Drug intelligence / Profile preview

ABI-H0731 + nucleos(t)ide + peginterferon alfa-2a

Development stage: Unknown
Lead developer: Assembly Biosciences
Modality: Recombinant Proteins and Enzymes, Small Molecules
Administration: Oral, Subcutaneous

Overview

ABI-H0731 + nucleos(t)ide + peginterferon alfa-2a is a combination investigational therapy for chronic hepatitis B virus (HBV) infection. **ABI-H0731 (vebicorvir)** is a small-molecule direct-acting antiviral that inhibits the HBV core protein, interfering with pregenomic RNA encapsidation and DNA replication, and disrupts HBV nucleocapsids, reducing new cccDNA formation. **Nucleos(t)ide analogues** (nucleoside/nucleotide reverse transcriptase inhibitors; NrtIs) inhibit HBV polymerase/reverse transcriptase, suppressing viral DNA synthesis. **Peginterferon alfa-2a** is a pegylated recombinant interferon stimulating the innate antiviral immune response via the JAK/STAT pathway and interferon alpha/beta receptors. The combination is aimed at achieving deeper or more durable HBV suppression than monotherapy by targeting multiple HBV lifecycle steps and stimulating host immunity.

Brand names: Pegasys
Other names: vebicorvirnucleoside analognucleotide analogpegylated interferon alfa-2a

Targets

HBc (Hepatitis B virus core protein)IFNAR2 (Interferon alpha/beta receptor subunit 2)IFNAR1 (Interferon alpha/beta receptor 1)HBV Pol (Hepatitis B virus polymerase)

Beyond the preview

Go deeper on ABI-H0731 + nucleos(t)ide + peginterferon alfa-2a.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ABI-H0731 + nucleos(t)ide + peginterferon alfa-2a.

Explore the full profile